MNPR Quote, Financials, Valuation and Earnings

Electromed has a net margin of -- compared to Monopar Therapeutics's net margin of 12.06%. Monopar Therapeutics's return on equity of -- beat Electromed's return on equity of 16.57%.

Monopar Therapeutics has a consensus price target of $61.27, signalling upside risk potential of 82.79%. On the other hand Electromed has an analysts' consensus of $38.00 which suggests that it could grow by 89.34%. Given that Electromed has higher upside potential than Monopar Therapeutics, analysts believe Electromed is more attractive than Monopar Therapeutics.

Monopar Therapeutics has a beta of 0.991, which suggesting that the stock is 0.87% less volatile than S&P 500. In comparison Electromed has a beta of 0.398, suggesting its less volatile than the S&P 500 by 60.159%.

Monopar Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Electromed offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Monopar Therapeutics pays -- of its earnings as a dividend. Electromed pays out -- of its earnings as a dividend.

Monopar Therapeutics quarterly revenues are --, which are smaller than Electromed quarterly revenues of $15.7M. Monopar Therapeutics's net income of -$2.6M is lower than Electromed's net income of $1.9M. Notably, Monopar Therapeutics's price-to-earnings ratio is -- while Electromed's PE ratio is 25.41x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Monopar Therapeutics is -- versus 2.93x for Electromed. Usually stocks with elevated PS ratios are considered overvalued.

Reshape Lifesciences has a net margin of -- compared to Monopar Therapeutics's net margin of -68.98%. Monopar Therapeutics's return on equity of -- beat Reshape Lifesciences's return on equity of -172.58%.

Monopar Therapeutics has a consensus price target of $61.27, signalling upside risk potential of 82.79%. On the other hand Reshape Lifesciences has an analysts' consensus of -- which suggests that it could grow by 57439.61%. Given that Reshape Lifesciences has higher upside potential than Monopar Therapeutics, analysts believe Reshape Lifesciences is more attractive than Monopar Therapeutics.

Monopar Therapeutics has a beta of 0.991, which suggesting that the stock is 0.87% less volatile than S&P 500. In comparison Reshape Lifesciences has a beta of 1.284, suggesting its more volatile than the S&P 500 by 28.358%.

Monopar Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Reshape Lifesciences offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Monopar Therapeutics pays -- of its earnings as a dividend. Reshape Lifesciences pays out -- of its earnings as a dividend.

Monopar Therapeutics quarterly revenues are --, which are smaller than Reshape Lifesciences quarterly revenues of $1.1M. Monopar Therapeutics's net income of -$2.6M is lower than Reshape Lifesciences's net income of $1.5M. Notably, Monopar Therapeutics's price-to-earnings ratio is -- while Reshape Lifesciences's PE ratio is 0.01x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Monopar Therapeutics is -- versus 0.01x for Reshape Lifesciences. Usually stocks with elevated PS ratios are considered overvalued.

VolitionRX has a net margin of -- compared to Monopar Therapeutics's net margin of -2201.34%. Monopar Therapeutics's return on equity of -- beat VolitionRX's return on equity of --.

Monopar Therapeutics has a consensus price target of $61.27, signalling upside risk potential of 82.79%. On the other hand VolitionRX has an analysts' consensus of $2.93 which suggests that it could grow by 362.44%. Given that VolitionRX has higher upside potential than Monopar Therapeutics, analysts believe VolitionRX is more attractive than Monopar Therapeutics.

Monopar Therapeutics has a beta of 0.991, which suggesting that the stock is 0.87% less volatile than S&P 500. In comparison VolitionRX has a beta of 1.072, suggesting its more volatile than the S&P 500 by 7.247%.

Monopar Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. VolitionRX offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Monopar Therapeutics pays -- of its earnings as a dividend. VolitionRX pays out -- of its earnings as a dividend.

Monopar Therapeutics quarterly revenues are --, which are smaller than VolitionRX quarterly revenues of $246.4K. Monopar Therapeutics's net income of -$2.6M is higher than VolitionRX's net income of -$5.4M. Notably, Monopar Therapeutics's price-to-earnings ratio is -- while VolitionRX's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Monopar Therapeutics is -- versus 43.82x for VolitionRX. Usually stocks with elevated PS ratios are considered overvalued.

Xtant Medical Holdings has a net margin of -- compared to Monopar Therapeutics's net margin of 0.18%. Monopar Therapeutics's return on equity of -- beat Xtant Medical Holdings's return on equity of -26.62%.

Monopar Therapeutics has a consensus price target of $61.27, signalling upside risk potential of 82.79%. On the other hand Xtant Medical Holdings has an analysts' consensus of $1.75 which suggests that it could grow by 181.13%. Given that Xtant Medical Holdings has higher upside potential than Monopar Therapeutics, analysts believe Xtant Medical Holdings is more attractive than Monopar Therapeutics.

Monopar Therapeutics has a beta of 0.991, which suggesting that the stock is 0.87% less volatile than S&P 500. In comparison Xtant Medical Holdings has a beta of -0.181, suggesting its less volatile than the S&P 500 by 118.091%.

Monopar Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Xtant Medical Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Monopar Therapeutics pays -- of its earnings as a dividend. Xtant Medical Holdings pays out -- of its earnings as a dividend.

Monopar Therapeutics quarterly revenues are --, which are smaller than Xtant Medical Holdings quarterly revenues of $32.9M. Monopar Therapeutics's net income of -$2.6M is lower than Xtant Medical Holdings's net income of $58K. Notably, Monopar Therapeutics's price-to-earnings ratio is -- while Xtant Medical Holdings's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Monopar Therapeutics is -- versus 0.70x for Xtant Medical Holdings. Usually stocks with elevated PS ratios are considered overvalued.